Fig. 3From: Development and validation of an LC-MS/MS method for monitoring larotrectinib, a tropomyosin-related kinase inhibitor, in mouse and human plasma and application to pharmacokinetic studiesTemporal profiles of larotrectinib concentrations in mouse plasma after an intravenous or oral administration of larotrectinib to mice (mean ± standard deviation, n = 3)Back to article page